On this page, you will find different kinds of study results:
• A Lay summary which is a summary of clinical trial results written in an easy-to-understand way.
• A summary of results called synopsis which is written in scientific language. It is prepared for Medicines Agencies and Ethics Committees,
• A scientific publication which presents results for scientists and medical doctors.
226 Results
Protocol Code |
Study Title |
Active substance/Medical device |
Study Phase |
Therapeutic Area |
CL1-95029-001 |
A Phase 1a/1b, Open-label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Anti-neoplastic Activity of…
|
S095029
|
Phase 1
|
Cancers
|
|
AG120-881-C-001 |
A Phase 1, Multicenter, Randomized, Controlled, Open-label, Perioperative Study of AG-120 and AG-881 in Subjects…
|
AG-120, AG881
|
Phase 1
|
Cancers
|
|
AG270-C-001 |
A Phase 1 Study of AG-270 in the Treatment of Subjects With Advanced Solid Tumors…
|
AG-270
|
Phase 1
|
Cancers
|
|
AG120-C-009 |
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in…
|
AG-120, Ivosidenib
|
Phase 3
|
Cancers
|
|
AG120-C-002 |
A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study…
|
AG-120
|
Phase 1
|
Cancers
|
|
AG120-C-001 |
A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study…
|
AG-120
|
Phase 1
|
Cancers
|
|
AG120-221-C-001 |
A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination With Induction…
|
AG-120, AG-221
|
Phase 1
|
Cancers
|
|
CL2-95014-002 |
A Multicentre, Phase II Randomized Study, Open-label, With 2-arm Parallel Group, Comparing the Pharmacokinetics of…
|
PEGASPARGASE, S095014
|
Phase 2
|
Cancers
|
|
CL2-95014-003 |
A Multicentre, Roll-over Study to Provide Continued Treatment With Lyophilized Pegaspargase (S95014) in Pediatric Patients…
|
PEGASPARGASE, S095014
|
Phase 2
|
Cancers
|
|
CL1-RTCMP-001 |
Target Involvement and Exploratory Biomarkers Investigations in Healthy Volunteers and in Patients With Type 2…
|
|
Phase 1
|
Metabolism
|
|
CL2-95015-001 |
A Multi-center, Open-label, Single-arm Phase 2/3 Trial Evaluating the Safety and Pharmacokinetics of Calaspargase Pegol…
|
Calaspargase pegol, S095015
|
Phase 2-3
|
Cancers
|
|
CL2-62798-010 |
A Multicentre, Randomized, Double-blind, Placebo-controlled Dose-finding Study of S62798 in Patients with Intermediate-High Risk Acute…
|
S062798
|
Phase 2
|
Cardiovascular Diseases
|
|
CL1-65487-003 |
Phase I / II, Open Label, Dose Escalation Part (Phase I) Followed by Noncomparative Expansion…
|
S065487
|
Phase 1-2
|
Cancers
|
|
CL3-95005-007 |
An open-label, randomised, phase III study comparing trifluridine/tipiracil in combination with bevacizumab to trifluridine/tipiracil monotherapy…
|
TIPIRACIL, TRIFLURIDINE, S095005
|
Phase 3
|
Cancers
|
|
CL1-64315-004 |
Phase I/II, international, multicentre, open-label, non-randomised, non-comparative, study evaluating the safety, tolerability and clinical activity…
|
S064315
|
Phase 1-2
|
Cancers
|
|
CL2-95011-001 |
A phase IIa efficacy and safety trial with intravenous S95011 in primary Sjögren’s Syndrome patients.…
|
S095011
|
Phase 2
|
Immune-Inflammatory Diseases
|
|
CL3-05167-005 |
Efficacy and safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in adult patients with arterial…
|
ATORVASTATIN, PERINDOPRIL, S005167
|
Phase 3
|
Cardiovascular Diseases
|
|
CL1-95014-001 |
A Phase 2 Clinical Study of Pegaspargase in Patients With Newly Diagnosed, Untreated Acute Lymphoblastic…
|
PEGASPARGASE, S095014
|
Phase 2
|
Cancers
|
|
CL1-64315-003 |
A Phase I/II, open label, non-randomized study to evaluate safety, tolerability, pharmacokinetics and clinical activity…
|
S064315
|
Phase 1-2
|
Cancers
|
|
CL3-13001-002 |
Clinical Investigation to Determine the Accuracy and Benefit of Cardioskin™ in Patients With Known Atrial…
|
Cardioskin™
|
Phase 3
|
Cardiovascular Diseases
|
|
331501 |
Phase II Randomized Study of BAX2398 in Combination With 5-Fluorouracil and Calcium Levofolinate in Japanese…
|
Liposomal Irinotecan, S095013
|
Phase 2
|
Cancers
|
|
CL1-65487-002 |
Study of a New Intravenous Drug, Called S065487, in Patients With Acute Myeloid Leukemia, Non…
|
S065487
|
Phase 1
|
Cancers
|
|
CL1-64315-002 |
An International Phase Ib Multicentre Study to Characterize the Safety and Tolerability of Intravenously Administered…
|
S064315
|
Phase 1
|
Cancers
|
|
CL3-95008-002 |
Efficacy and safety of bumetanide oral liquid formulation in children aged from 2 to less…
|
BUMETANIDE, S095008
|
Phase 3
|
Neuropsychiatric Diseases
|
|
CL3-95008-001 |
Efficacy and safety of bumetanide oral liquid formulation in children and adolescents aged from 7…
|
BUMETANIDE, S095008
|
Phase 3
|
Neuropsychiatric Diseases
|
|
Servier clinical trials are mainly registered on
EU Clinical Trials Register
The EU Clinical Trials Register contains information on interventional clinical trials on medicines carried out in Europe, which started after 1 May 2004.
SEE MORE
ClinicalTrials.gov
Clinicaltrials.gov is a registry that contains information on clinical studies of human participants carried out around the world.
SEE MORE
ISRCTN registry
The International Standard Randomized Controlled Trial Number (ISRCTN) registry is a primary clinical trial registry recognised by World Health Organization (WHO) and International Committee of Medical Journal Editor (ICMJE) that accepts all clinical research studies.
SEE MORE